Navigation Links
Celator(R) Pharmaceuticals to Present at 2008 BIO International Convention
Date:6/16/2008

PRINCETON, N.J., June 16 /PRNewswire/ -- Celator Pharmaceuticals today announced that John Bennett, head of business development, is scheduled to present at the BIO Business Forum during the Biotechnology Industry Organization (BIO) International Convention in San Diego. Mr. Bennett will provide a corporate overview and an update on Celator's clinical development programs. The presentation will be held on Wednesday, June 18, 2008 at 3:30 PDT in Room 3 of the San Diego Convention Center.

About Celator

Celator Pharmaceuticals, Inc., is a privately held pharmaceutical company working to develop new and more effective therapies to treat cancer. CombiPlex(TM), the company's drug ratio technology platform, represents a revolutionary new approach to the development of combination therapies based on identifying a fixed, synergistic ratio of the drugs pre-clinically, incorporating that ratio in a drug delivery vehicle and maintaining the ratio in patients. The company pipeline includes: CPX-1 (a liposomal formulation of irinotecan:floxuridine), currently in a Phase 2 trial in patients with colorectal cancer; CPX-351 (a liposomal formulation of cytarabine:daunorubicin), currently in a Phase 1 trial in patients with leukemia; CPX 571 (a liposomal formulation of irinotecan:cisplatin), a preclinical stage compound; and multiple research programs. Based on the applications of CombiPlex, Celator is positioned to advance a broad pipeline of combination therapies involving both previously approved and novel drug agents. For more information, please visit the company's website at http://www.celatorpharma.com.


'/>"/>
SOURCE Celator Pharmaceuticals
Copyright©2008 PR Newswire.
All rights reserved

Page: 1

Related biology technology :

1. Celator(R) Pharmaceuticals Announces Appointment of Scott Jackson as CEO
2. Celator(R) Pharmaceuticals to Present at 10th Annual BIO CEO and Investor Conference
3. Celator(R) Pharmaceuticals Study Shows CPX-571 Maintains Synergistic Ratio of Irinotecan and Cisplatin to Improve Anti-tumor Activity
4. Scimitar Equity, LLC Initiates Coverage Review of VioQuest Pharmaceuticals, Inc.
5. GlaxoSmithKline and Mpex Pharmaceuticals Form Alliance to Develop Novel Efflux Pump Inhibitors for Use Against Serious Gram-Negative Infections
6. Raptor Pharmaceuticals Corp. To Present at BIO 2008 International Convention
7. Jazz Pharmaceuticals Files Form S-3 Registration Statements
8. Quark Pharmaceuticals to Participate in 9th Annual Beyond Genome Conference
9. Merrimack Pharmaceuticals Raises $60 Million in Private Financing
10. The Leukemia & Lymphoma Society and Provid Pharmaceuticals Announce Collaboration on Treatment for Acute Myelogenous Leukemia
11. Diffusion Pharmaceuticals Announces Addition of Mark T. Giles to its Board of Directors
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/18/2017)... ... February 17, 2017 , ... The ... and the Center for International Blood & Marrow Transplant Research (CIBMTR) will take ... , The combined scientific sessions offer investigators, clinicians, laboratory technicians, clinical ...
(Date:2/17/2017)... 17, 2017  BioGenex, a global leader in ... a novel system for quantitative immunohistochemistry (IHC). The ... of Rochester (NY, USA) and Konica-Minolta Inc. ( ... is able to accurately quantify the expression of ... growth factor receptor-2) in clinical samples. Quantitative IHC ...
(Date:2/16/2017)... ... February 16, 2017 , ... EIT Digital ... aimed at the agricultural industry. Pilot studies are about to get under way for ... Big Data and 5G innovations. The concept is expected to be transferred eventually to ...
(Date:2/16/2017)... WEST PALM BEACH, Fla. , Feb. 16, ... molecular diagnostics company revolutionizing the development of liquid ... that it has entered into an exclusive license ... who will distribute MDNA,s proprietary liquid biopsy test ... in South Korea . This ...
Breaking Biology Technology:
(Date:2/14/2017)... -- Wake Forest Baptist Medical Center today announced Julie Ann Freischlag, ... (CEO). Freischlag joins the medical center on May 1 ... who last year announced that he would transition to ... it since 2008.   As CEO, Freischlag ... academic health system, which includes Wake Forest School of ...
(Date:2/13/2017)... WASHINGTON , Feb. 13, 2017 Former ... U.S. Senate Judiciary Committee, Janice Kephart of ... regarding President Donald Trump,s "Executive Order: Protecting ... States" (Jan. 27, 2017):  "As President Trump,s ... 9th Circuit has now essentially banned the travel ban, ...
(Date:2/9/2017)... LONDON , Feb. 9, 2017 The ... in-depth analysis of the biomass boiler market globally in ... sales of biomass boilers. The market for biomass boilers ... product type, end-user, application, and country/region. The market based ... agriculture & forest residues, biogas & energy crops, urban ...
Breaking Biology News(10 mins):